High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial is a research paper published in Clinical Infectious Diseases (2021). On theSindex it has a DataRank of 0.661. It has been cited 81 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.661
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Wellcome Trust
Grant: 107743
Makerere University UVRI Centre of Excellence for Infection & Immunity Research and Training (MUII-plus)
Wellcome Trust
Grant: 210772/Z/18/Z
Medical Research Council
Grant: MC_UP_1204/15
FIC NIH HHS
Grant: D43 TW009771
Medical Research Council
Grant: MC_UU_00027/5
Medical Research Council
Grant: MR/R010161/1
Wellcome Trust
Grant: 210772
Improving diagnosis and treatment of TB meningitis
National Institutes of Health
NIH HHS
FWCI
10.74
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals